SG11202104918PA - Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l - Google Patents

Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Info

Publication number
SG11202104918PA
SG11202104918PA SG11202104918PA SG11202104918PA SG11202104918PA SG 11202104918P A SG11202104918P A SG 11202104918PA SG 11202104918P A SG11202104918P A SG 11202104918PA SG 11202104918P A SG11202104918P A SG 11202104918PA SG 11202104918P A SG11202104918P A SG 11202104918PA
Authority
SG
Singapore
Prior art keywords
cd137l
1bbl
cd40l
intratumoral
therapy
Prior art date
Application number
SG11202104918PA
Inventor
Henning Lauterbach
Maria Hinterberger
Echeverz Jose Medina
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of SG11202104918PA publication Critical patent/SG11202104918PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202104918PA 2018-11-20 2019-11-20 Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l SG11202104918PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18207238 2018-11-20
US201962807720P 2019-02-19 2019-02-19
PCT/EP2019/081942 WO2020104531A1 (en) 2018-11-20 2019-11-20 Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Publications (1)

Publication Number Publication Date
SG11202104918PA true SG11202104918PA (en) 2021-06-29

Family

ID=68542659

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104918PA SG11202104918PA (en) 2018-11-20 2019-11-20 Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l

Country Status (11)

Country Link
EP (1) EP3883599A1 (en)
JP (1) JP2022507744A (en)
KR (1) KR20210094535A (en)
CN (1) CN113056284A (en)
AU (1) AU2019385665A1 (en)
BR (1) BR112021009856A8 (en)
CA (1) CA3119503A1 (en)
IL (1) IL283187A (en)
MX (1) MX2021005560A (en)
SG (1) SG11202104918PA (en)
WO (1) WO2020104531A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
KR20220116191A (en) 2019-11-20 2022-08-22 버베리안 노딕 에이/에스 Pharmaceutical Use of 4-1BBL Adjuvanted Recombinant Modified Vaccinia Virus Ankara (MVA)
IL293009A (en) * 2019-11-20 2022-07-01 Bavarian Nordic As Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
WO2021207171A1 (en) * 2020-04-06 2021-10-14 St. Jude Children's Research Hospital, Inc. B7-h3 chimeric antigen receptors
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
MXPA01003503A (en) 1998-10-05 2005-01-14 Pharmexa As Novel methods for therapeutic vaccination.
IL154712A0 (en) 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
EP1461073B1 (en) 2001-11-30 2010-01-06 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Peptide agonists of prostate-specific antigen, and uses therefor
EP2345665A3 (en) 2001-12-04 2012-02-15 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CA2860599C (en) 2012-01-03 2021-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
AU2013331328B2 (en) 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
UA118340C2 (en) 2012-10-28 2019-01-10 Баваріан Нордік А/С Pr13.5 promoter for robust t-cell and antibody responses
US20170266270A1 (en) * 2014-05-13 2017-09-21 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
KR20150135148A (en) 2014-05-23 2015-12-02 주식회사 제넥신 PD-L1 Fused protein and use thereof
IL256869B (en) 2015-07-31 2022-07-01 Bavarian Nordic As Promoters for enhancing expression in poxvirus

Also Published As

Publication number Publication date
MX2021005560A (en) 2021-06-23
KR20210094535A (en) 2021-07-29
IL283187A (en) 2021-06-30
JP2022507744A (en) 2022-01-18
AU2019385665A1 (en) 2021-05-27
BR112021009856A2 (en) 2021-08-17
EP3883599A1 (en) 2021-09-29
BR112021009856A8 (en) 2021-09-08
WO2020104531A1 (en) 2020-05-28
CA3119503A1 (en) 2020-05-28
CN113056284A (en) 2021-06-29

Similar Documents

Publication Publication Date Title
IL283187A (en) Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
SG10201908269SA (en) Modulation of tumor immunity by protein-mediated o2 delivery
MX2022010270A (en) A novel approach for treatment of cancer using immunomodulation.
IL290695A (en) Combination cancer therapy and cytokine control therapy for cancer treatment
IL248507A0 (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
MX2016005980A (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors.
BR112018067731A2 (en) glucagon and glp-1 coagonists for obesity treatment
IL280637A (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
SG10201808218YA (en) Gene therapy for retinitis pigmentosa
IL289518A (en) Recombinant ad35 vectors and related gene therapy improvements
PH12014502738A1 (en) High-xten fusion protein and its use in the treatment of growth hormone deficiency
MX2017006938A (en) Combination therapy for treatment of cancer.
MX2017009044A (en) Method for the treatment of malignancies.
IL281988A (en) Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
IL275550A (en) Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
IL272546B1 (en) Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
EP3888648A4 (en) Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy
MX2018010847A (en) Combination therapy using a liv1-adc and a chemotherapeutic.
IL281016A (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
MX2022005664A (en) Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer.
SG11202111476RA (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
IL292247A (en) Methods for treating patients having cfh mutations with recombinant cfh proteins
IL288178A (en) Gmci and ddri combination therapy for treating cancer
IL289768A (en) Device for nuclear magnetic resonance therapy
EP4065099A4 (en) Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer